Ticker Update
Positive Clinical Trial Data Boosts Capricor (CAPR) Shares
Capricor Therapeutics, Inc. (NASDAQ: CAPR) has reported encouraging additional safety data from its ongoing clinical trial, resulting in an upward trajectory for its shares. At the latest market check, CAPR stock increased to $4.80 rising 3.54% on the stock charts. Promising HOPE-2 Study Results Capricor